Log In
BCIQ
Print this Print this
 

p16_37-83 peptide, VicOryx

  Manage Alerts
Collapse Summary General Information
Company Oryx GmbH & Co. KG
DescriptionVaccine comprising a synthetic cyclin dependent kinase inhibitor 2A (CDKN2A; INK4a; ARF; p16INK4a) peptide
Molecular Target Cyclin dependent kinase inhibitor 2A (CDKN2A) (INK4a) (ARF) (p16INK4a)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I/II
Standard Indication Cancer (unspecified)
Indication DetailsTreat HPV-associated cancers
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today